HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $115

Benzinga Newsdesk www.benzinga.com Positive 62.5%

Neg 0% Neu 0% Pos 62.5%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $95 to $115.